Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, Buttard B, Rothe F, Willard-Gallo K, Haller A, Ninane V, Burny A, Sculier JP, Spira A, Galon J.

Nature. 2019 Jul;571(7766):570-575. doi: 10.1038/s41586-019-1330-0. Epub 2019 Jun 26.

PMID:
31243362
2.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazières J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 May 24. pii: mdz167. doi: 10.1093/annonc/mdz167. [Epub ahead of print]

PMID:
31125062
3.

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA.

Clin Lung Cancer. 2019 May;20(3):e338-e345. doi: 10.1016/j.cllc.2018.12.009. Epub 2018 Dec 19.

PMID:
30770327
4.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, Chaleat S, Khobta N, Milia J, Mhanna L, Greillier L, Biemar J, Nanni I, Ouafik L, Garcia S, Mazières J, Barlesi F, Mascaux C.

J Thorac Oncol. 2019 Jun;14(6):1095-1101. doi: 10.1016/j.jtho.2019.01.011. Epub 2019 Feb 6.

PMID:
30738221
5.

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.

Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, Boucekine M, Mascaux C, Barlesi F.

Clin Lung Cancer. 2019 May;20(3):201-207. doi: 10.1016/j.cllc.2018.10.002. Epub 2018 Oct 11.

PMID:
30442524
6.

[Autoimmune-related bleeding occurring during combined immunotherapy for lung cancer - Case report].

Eberst G, Lakhzoum W, Tomasini P, Andreotti N, Abcaya J, Mascaux C, Barlesi F.

Rev Mal Respir. 2018 Nov;35(9):974-977. doi: 10.1016/j.rmr.2018.01.013. Epub 2018 Oct 11. French.

PMID:
30318433
7.

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.

Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA.

Lung Cancer. 2018 Sep;123:22-29. doi: 10.1016/j.lungcan.2018.06.023. Epub 2018 Jun 19.

PMID:
30089591
8.

Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma.

Sharpnack MF, Ranbaduge N, Srivastava A, Cerciello F, Codreanu SG, Liebler DC, Mascaux C, Miles WO, Morris R, McDermott JE, Sharpnack JL, Amann J, Maher CA, Machiraju R, Wysocki VH, Govindan R, Mallick P, Coombes KR, Huang K, Carbone DP.

J Thorac Oncol. 2018 Oct;13(10):1519-1529. doi: 10.1016/j.jtho.2018.06.025. Epub 2018 Jul 11.

PMID:
30017829
9.

CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases.

Henry A, Boulagnon-Rombi C, Menguy T, Giustiniani J, Garbar C, Mascaux C, Labrousse M, Milas C, Barbe C, Bensussan A, Durlach V, Arndt C.

Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2679-2686. doi: 10.1167/iovs.18-24021.

PMID:
29860454
10.

Triple-negative and HER2-overexpressing breast cancer cell sialylation impacts tumor microenvironment T-lymphocyte subset recruitment: a possible mechanism of tumor escape.

Garbar C, Mascaux C, Merrouche Y, Bensussan A.

Cancer Manag Res. 2018 May 4;10:1051-1059. doi: 10.2147/CMAR.S162932. eCollection 2018.

11.

Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).

Dhont L, Pintilie M, Kaufman E, Navab R, Tam S, Burny A, Shepherd F, Belayew A, Tsao MS, Mascaux C.

BMC Cancer. 2018 Apr 16;18(1):429. doi: 10.1186/s12885-018-4215-y.

12.

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C.

Eur Respir Rev. 2018 Mar 14;27(147). pii: 170098. doi: 10.1183/16000617.0098-2017. Print 2018 Mar 31. Review.

13.

Genomic Testing in Lung Cancer: Past, Present, and Future.

Mascaux C, Tsao MS, Hirsch FR.

J Natl Compr Canc Netw. 2018 Mar;16(3):323-334. doi: 10.6004/jnccn.2017.7019. Review.

PMID:
29523671
14.

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.

Imbs DC, El Cheikh R, Boyer A, Ciccolini J, Mascaux C, Lacarelle B, Barlesi F, Barbolosi D, Benzekry S.

CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):42-50. doi: 10.1002/psp4.12265. Epub 2017 Dec 7.

15.

Personalised medicine for nonsmall cell lung cancer.

Mascaux C, Tomasini P, Greillier L, Barlesi F.

Eur Respir Rev. 2017 Nov 15;26(146). pii: 170066. doi: 10.1183/16000617.0066-2017. Print 2017 Dec 31. Review.

16.

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, Liu G, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA.

Lung Cancer. 2017 Sep;111:23-29. doi: 10.1016/j.lungcan.2017.06.014. Epub 2017 Jun 24.

PMID:
28838393
17.

Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231.

Garbar C, Mascaux C, Giustiniani J, Merrouche Y, Bensussan A.

Sci Rep. 2017 Aug 3;7(1):7201. doi: 10.1038/s41598-017-07489-x.

18.

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.

Barlesi F, Imbs DC, Tomasini P, Greillier L, Galloux M, Testot-Ferry A, Garcia M, Elharrar X, Pelletier A, André N, Mascaux C, Lacarelle B, Cheikh RE, Serre R, Ciccolini J, Barbolosi D.

Oncotarget. 2017 Jul 18;8(29):47161-47166. doi: 10.18632/oncotarget.17562.

19.

Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.

Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, Chung C, Shepherd FA.

Radiother Oncol. 2017 May;123(2):195-202. doi: 10.1016/j.radonc.2017.03.007. Epub 2017 Mar 28.

PMID:
28363487
20.

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.

Tomasini P, Serdjebi C, Khobta N, Metellus P, Ouafik L, Nanni I, Greillier L, Loundou A, Fina F, Mascaux C, Barlesi F.

Int J Mol Sci. 2016 Dec 18;17(12). pii: E2132. doi: 10.3390/ijms17122132.

21.

Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models.

Hubaux R, Vandermeers F, Cosse JP, Crisanti C, Kapoor V, Albelda SM, Mascaux C, Delvenne P, Hubert P, Willems L.

ERJ Open Res. 2015 Oct 19;1(2). pii: 00028-2015. eCollection 2015 Oct.

22.

Elderly selection on geriatric index assessment.

Tomasini P, Mascaux C, Barlesi F.

Ann Transl Med. 2016 Jun;4(12):245. doi: 10.21037/atm.2016.05.61. No abstract available.

23.

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes.

Tomasini P, Barlesi F, Mascaux C, Greillier L.

Ther Adv Med Oncol. 2016 May;8(3):198-208. doi: 10.1177/1758834016644155. Epub 2016 May 9. Review.

24.

Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.

Martin P, Stewart E, Pham NA, Mascaux C, Panchal D, Li M, Kim L, Sakashita S, Wang D, Sykes J, Friess T, Shepherd FA, Liu G, Tsao MS.

Clin Lung Cancer. 2016 Sep;17(5):375-383.e2. doi: 10.1016/j.cllc.2016.01.002. Epub 2016 Jan 22.

PMID:
26926157
25.

The helicase-like transcription factor (HLTF) in cancer: loss of function or oncomorphic conversion of a tumor suppressor?

Dhont L, Mascaux C, Belayew A.

Cell Mol Life Sci. 2016 Jan;73(1):129-47. Review.

PMID:
26472339
26.

Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.

Garbar C, Mascaux C, Giustiniani J, Salesse S, Debelle L, Antonicelli F, Merrouche Y, Bensussan A.

Int J Clin Exp Pathol. 2015 May 1;8(5):4344-55. eCollection 2015.

27.

Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.

Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS.

J Clin Oncol. 2015 Aug 1;33(22):2472-80. doi: 10.1200/JCO.2014.60.1492. Epub 2015 Jun 29.

PMID:
26124487
28.

Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European Lung Cancer Working Party.

Berghmans T, Ameye L, Lafitte JJ, Colinet B, Cortot A, CsToth I, Holbrechts S, Lecomte J, Mascaux C, Meert AP, Paesmans M, Richez M, Scherpereel A, Tulippe C, Willems L, Dernies T, Leclercq N, Sculier JP; European Lung Cancer Working Party.

Front Oncol. 2015 Jan 28;4:386. doi: 10.3389/fonc.2014.00386. eCollection 2014.

30.

Bronchial airway gene expression in smokers with lung or head and neck cancer.

Van Dyck E, Nazarov PV, Muller A, Nicot N, Bosseler M, Pierson S, Van Moer K, Palissot V, Mascaux C, Knolle U, Ninane V, Nati R, Bremnes RM, Vallar L, Berchem G, Schlesser M.

Cancer Med. 2014 Apr;3(2):322-36. doi: 10.1002/cam4.190. Epub 2014 Feb 4.

31.

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.

Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Curé H, Mascaux C, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A, Bastid J.

Sci Rep. 2013 Dec 9;3:3456. doi: 10.1038/srep03456.

32.

Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.

Berghmans T, Ameye L, Willems L, Paesmans M, Mascaux C, Lafitte JJ, Meert AP, Scherpereel A, Cortot AB, Cstoth I, Dernies T, Toussaint L, Leclercq N, Sculier JP; European Lung Cancer Working Party.

Lung Cancer. 2013 Nov;82(2):340-5. doi: 10.1016/j.lungcan.2013.07.020. Epub 2013 Aug 7.

PMID:
24007627
33.

Adjuvant chemotherapy after pulmonary resection for lung cancer.

Mascaux C, Shepherd FA.

Thorac Surg Clin. 2013 Aug;23(3):401-10. doi: 10.1016/j.thorsurg.2013.04.005. Epub 2013 Jun 4. Review.

PMID:
23931022
34.

Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era.

Brothers JF, Hijazi K, Mascaux C, El-Zein RA, Spitz MR, Spira A.

BMC Med. 2013 Jul 19;11:168. doi: 10.1186/1741-7015-11-168. Review.

35.

Muc1/Cd227 immunohistochemistry in routine practice is a useful biomarker in breast cancers.

Garbar C, Mascaux C, Curé H, Bensussan A.

J Immunoassay Immunochem. 2013;34(3):232-45. doi: 10.1080/15321819.2012.699491.

PMID:
23656244
36.

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C, Hirsch FR.

Cell Oncol (Dordr). 2013 Jul;36(4):277-88. doi: 10.1007/s13402-013-0133-9. Epub 2013 Apr 26.

37.

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

Zielinski C, Knapp S, Mascaux C, Hirsch F.

Ann Oncol. 2013 May;24(5):1170-9. doi: 10.1093/annonc/mds647. Epub 2013 Feb 7. Review.

38.

Endobronchial miRNAs as biomarkers in lung cancer chemoprevention.

Mascaux C, Feser WJ, Lewis MT, Barón AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR.

Cancer Prev Res (Phila). 2013 Feb;6(2):100-8. doi: 10.1158/1940-6207.CAPR-12-0382. Epub 2012 Dec 26.

39.

Screening and early detection of lung cancer.

Vansteenkiste J, Dooms C, Mascaux C, Nackaerts K.

Ann Oncol. 2012 Sep;23 Suppl 10:x320-7.

PMID:
22987984
40.

Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WE, Hirsch FR.

J Thorac Oncol. 2012 Sep;7(9):1440-8.

42.

EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.

Mascaux C, Wynes MW, Kato Y, Tran C, Asuncion BR, Zhao JM, Gustavson M, Ranger-Moore J, Gaire F, Matsubayashi J, Nagao T, Yoshida K, Ohira T, Ikeda N, Hirsch FR.

Clin Cancer Res. 2011 Dec 15;17(24):7796-807. doi: 10.1158/1078-0432.CCR-11-0209. Epub 2011 Oct 12.

43.

C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.

CsToth I, Anthoine G, Berghmans T, Mascaux C, Paesmans M, Sculier JP, Meert AP.

Anticancer Res. 2011 Jan;31(1):281-5.

PMID:
21273611
44.

Early detection and screening of lung cancer.

Mascaux C, Peled N, Garg K, Kato Y, Wynes MW, Hirsch FR.

Expert Rev Mol Diagn. 2010 Sep;10(6):799-815. doi: 10.1586/erm.10.60. Review.

PMID:
20843203
45.

Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.

Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, Ohira T, Tsuboi M, Matsubayashi J, Nagao T, Ikeda N, Hirsch FR.

J Thorac Oncol. 2010 Oct;5(10):1551-8. doi: 10.1097/JTO.0b013e3181e9da60.

46.

Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.

Hubaux R, Vandermeers F, Crisanti MC, Kapoor V, Burny A, Mascaux C, Albelda SM, Willems L.

Eur J Cancer. 2010 Jun;46(9):1724-34. doi: 10.1016/j.ejca.2010.03.021. Epub 2010 May 5. Erratum in: Eur J Cancer. 2010 Nov;46(17):3127. Crisanti, Cecilia [corrected to Crisanti, M Cecilia].

PMID:
20451370
47.

Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project.

Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, Mascaux C, Meert AP, Roelandts M, Scherpereel A, Terrones Munoz V, Sculier JP; European Lung Cancer Working Party, and on behalf of the IASLC Lung Cancer Staging Project.

J Thorac Oncol. 2010 May;5(5):612-9. doi: 10.1097/JTO.0b013e3181d0a4f5.

48.

Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.

Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L.

Clin Cancer Res. 2009 Apr 15;15(8):2818-28. doi: 10.1158/1078-0432.CCR-08-1579. Epub 2009 Apr 7.

50.

[Etiology, epidemiology, biology. Lung carcinogenesis].

Mascaux C.

Rev Mal Respir. 2008 Oct;25(8 Pt 2):3S32-9. French.

PMID:
18971824

Supplemental Content

Loading ...
Support Center